MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

Search

Cytokinetics Inc

Suletud

SektorTervishoid

37.5 -6.67

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

37.32

Max

40.37

Põhinäitajad

By Trading Economics

Sissetulek

11M

-150M

Müük

16M

17M

Aktsiakasum

-1.26

Kasumimarginaal

-886.276

Töötajad

498

EBITDA

13M

-125M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+117.15% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

7. mai 2025

Turustatistika

By TradingEconomics

Turukapital

-723M

5.1B

Eelmine avamishind

44.17

Eelmine sulgemishind

37.5

Uudiste sentiment

By Acuity

75%

25%

342 / 386 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Bearish Evidence

Cytokinetics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

5. juuni 2024, 15:26 UTC

Omandamised, ülevõtmised, äriostud

Cytokinetics CEO Says Board Would Have Backed Actionable Buyout

5. juuni 2024, 14:14 UTC

Omandamised, ülevõtmised, äriostud

Cytokinetics: Board, Management Would Never Stand in Way of Value-Maximizing Transaction >CYTK

5. juuni 2024, 14:14 UTC

Omandamised, ülevõtmised, äriostud

Cytokinetics CEO: Board Would Have Supported Actionable Proposal in Best Interests of Shareholders >CYTK

5. juuni 2024, 14:14 UTC

Omandamised, ülevõtmised, äriostud

WSJ Reported in January That Novartis Backed Away From Pursuit of Cytokinetics >CYTK

5. juuni 2024, 14:14 UTC

Omandamised, ülevõtmised, äriostud

Cytokinetics CEO: Other Party Didn't Move Forward With Acquisition >CYTK

5. juuni 2024, 14:14 UTC

Omandamised, ülevõtmised, äriostud

Cytokinetics CEO: Board Was Supportive of Moving Forward on Deal on Terms Company Believed Would Be Mutually Acceptable >CYTK

5. juuni 2024, 14:14 UTC

Omandamised, ülevõtmised, äriostud

Cytokinetics CEO: Previously Held Good-Faith Talks With Another Party on Acquisition of Company >CYTK

Võrdlus sarnastega

Hinnamuutus

Cytokinetics Inc Prognoos

Hinnasiht

By TipRanks

117.15% tõus

12 kuu keskmine prognoos

Keskmine 81.43 USD  117.15%

Kõrge 120 USD

Madal 62 USD

Põhineb 17 Wall Streeti analüütiku instrumendi Cytokinetics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

17 ratings

16

Osta

1

Hoia

0

Müü

Tehniline skoor

By Trading Central

N/A / 42.705Toetus ja vastupanu

Lühikene perspektiiv

Bearish Evidence

Keskpikk perspektiiv

Strong Bearish Evidence

Pikk perspektiiv

Bearish Evidence

Sentiment

By Acuity

342 / 386 Pingereas Tervishoid

Uudiste sentiment

Väga tugevad languse märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Cytokinetics Inc

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. It develops small molecule drug candidates primarily engineered to impact muscle function and contractility. The company's drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. It also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. The company has a strategic alliance with Ji Xing Pharmaceuticals Limited; and a collaboration and license agreement for the development and commercialization of aficamten in Japan for the treatment of patients with obstructive and non-obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.